Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients

被引:2
|
作者
Sultana, Camelia [1 ,2 ]
Casian, Mihnea [1 ,3 ]
Oprea, Cristiana [1 ,4 ]
Ianache, Irina [4 ]
Grancea, Camelia [2 ]
Chiriac, Daniela [2 ]
Ruta, Simona [1 ,2 ]
机构
[1] Carol Davila Univ Med & Pharm, Fac Med, Bucharest 050474, Romania
[2] Stefan S Nicolau Inst Virol, Emergent Dis Dept, Bucharest 030304, Romania
[3] Dr Carol Davila Cent Mil Emergency Hosp, Cardiol Dept 2, Bucharest 010825, Romania
[4] Dr Victor Babes Hosp Infect & Trop Dis, HIV SIDA Dept, Bucharest 030303, Romania
来源
MEDICINA-LITHUANIA | 2022年 / 58卷 / 04期
关键词
HIV-HBV co-infection; Romania; HBV genotypes; resistance-associated mutations; HIV pediatric cohort; injecting drug users; LAMIVUDINE RESISTANCE; DRUG; POLYMERASE; FAILURE;
D O I
10.3390/medicina58040531
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Romania has one of the highest prevalence of hepatitis B virus (HBV) infection in human immunodeficiency virus (HIV) patients, mostly in those parenterally infected during childhood; nevertheless, there are scarce data on the virological profile of co-infection. The objective of this study was to assess the prevalence of HBV genotypes and antiviral resistance-associated mutations (RAMs) in these co-infected patients, in order to monitor the viral factors associated with the evolution of liver disease. Materials and Methods: HBV genotypes and RAMs were detected using nested PCR and line probe assays (INNO-LiPA HBV genotyping assay, and INNO-LiPA HBV DR v2, Innogenetics). Results: Out of 117 co-infected patients, 73.5% had detectable HBV-DNA, but only 38.5% presented an HBV viral load >1000 IU/mL. HBV genotype A was present in 66.7% of the cases and was dominant in patients parenterally infected during early childhood, who experienced multiple treatment regimens, with a mean therapy length of 15.25 years, and present numerous mutations associated with lamivudine (LAM) resistance, but very rarely active liver disease. HBV genotype D was detected in 33.3% of the cases, mostly in recently diagnosed injecting drug users who are treatment naive, but, nevertheless, present RAMs in 63.5% of the cases, suggesting transmitted drug resistance, and display more frequently advanced liver fibrosis (36.1% vs. 12.3%; p = 0.033). The most frequently encountered RAMs are M204V/I: 48.8%, L180M: 33.3%, L80V: 28.8%, and V173L: 42.2%. There are no significant differences in the distribution of RAMs in patients infected with different HBV genotypes, except for the L80V and N236T mutations, which were more frequently found in HBV genotype A infections (p = 0.032 and p = 0.004, respectively). Conclusions: HBV genotypes A and D are the only genotypes present in HIV-HBV co-infected patients from Romania, with different distributions according to the infection route, and are frequently associated with multiple RAMs, conferring extensive resistance to LAM.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients
    Gelinck, LBS
    Claas, ECJ
    Kroon, FP
    [J]. JOURNAL OF HEPATOLOGY, 2005, 43 (02) : 360 - 361
  • [22] Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV
    Boyd, Anders
    Maylin, Sarah
    Gozlan, Joel
    Delaugerre, Constance
    Simon, Francois
    Girard, Pierre-Marie
    Lacombe, Karine
    [J]. LIVER INTERNATIONAL, 2015, 35 (03) : 795 - 804
  • [23] High Frequency of Lamivudine Resistance Mutations in Brazilian Patients Co-Infected With HIV and Hepatitis B
    Mendes-Correa, M. C.
    Pinho, J. R. R.
    Locarnini, S.
    Yuen, L.
    Sitnik, R.
    Santana, R. A. F.
    Gomes-Gouvea, M. S.
    Leite, O. M.
    Martins, L. G.
    Silva, M. H.
    Gianini, R. J.
    Uip, D. E.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (09) : 1481 - 1488
  • [24] Longitudinal evaluation of hepatitis B, C and/or D viremia in HIV-HBV co-infected patients: Virological interactions and effects of treatment
    Boyd, A.
    Lacombe, K.
    Serfaty, L.
    Miailhes, P.
    Gozlan, J.
    Bonnard, P.
    Molina, J. M.
    Lascoux-Combe, C.
    Desvarieux, M.
    Girard, R. M.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S246 - S246
  • [25] Characterisation and clinical significance of lamivudine resistant hepatitis B virus (HBV) mutations in human immunodeficiency virus (HIV) and HBV co-infected individuals
    Bartholomeusz, A
    Locarnini, S
    Ayres, A
    Cooley, L
    Lewin, S
    Crowe, S
    Mijch, A
    Roberts, S
    Sasadeusz, J
    [J]. ANTIVIRAL RESEARCH, 2003, 57 (03) : A43 - A43
  • [26] Management of hepatitis C in HIV and/or HBV co-infected patients
    Vicente Fernandez-Montero, Jose
    Soriano, Vicente
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (04) : 517 - 530
  • [27] Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients
    Selabe, S. Gloria
    Lukhwareni, Azwidowi
    Song, Ernest
    Leeuw, Yeegan G. M.
    Burnett, Rosemary J.
    Mphahlele, M. Jeffrey
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (11) : 1650 - 1654
  • [28] Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
    Urvi Rana
    Matt Driedger
    Paul Sereda
    Shenyi Pan
    Erin Ding
    Alex Wong
    Sharon Walmsley
    Marina Klein
    Deborah Kelly
    Mona Loutfy
    Rejean Thomas
    Stephen Sanche
    Abigail Kroch
    Nima Machouf
    Marie-Helene Roy-Gagnon
    Robert Hogg
    Curtis L. Cooper
    [J]. BMC Infectious Diseases, 19
  • [29] Treatment of hepatitis B virus (HBV) in the setting of HIV-HBV co-infection
    Iser, David M.
    Lewin, Sharon R.
    [J]. ASIAN BIOMEDICINE, 2009, 3 (01) : 15 - 27
  • [30] Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
    Rana, Urvi
    Driedger, Matt
    Sereda, Paul
    Pan, Shenyi
    Ding, Erin
    Wong, Alex
    Walmsley, Sharon
    Klein, Marina
    Kelly, Deborah
    Loutfy, Mona
    Thomas, Rejean
    Sanche, Stephen
    Kroch, Abigail
    Machouf, Nima
    Roy-Gagnon, Marie-Helene
    Hogg, Robert
    Cooper, Curtis L.
    [J]. BMC INFECTIOUS DISEASES, 2019, 19 (01)